Falsified antimalarials: a minireview

References

• WHO. World Malaria report 2014. World Health Organization; Geneva: 2014
   Google Scholar
• O’Connell KA, Gatakaa H, Poyer S, et al. Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries. Malar J 2011;10:326
   PubMed Web of Science ®Google Scholar
• White NJ. Qinghaosu (artemisinin): the price of success. Science 2008;320:330-4
   PubMed Web of Science ®Google Scholar
• WHO. Guidelines for the treatment of malaria, second edition 2010. Available from: www.who.int/malaria/publications/atoz/9789241547925/en/index.html [Accessed December 2014]
   Google Scholar
• Dondorp AM, Yeung S, White L, et al. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol 2010;8:272-80
   PubMed Web of Science ®Google Scholar
• Burrows JN, van Huijsduijnen RH, Mohrle JJ, et al. Designing the next generation of medicines for malaria control and eradication. Malar J 2013;12:187
   PubMed Web of Science ®Google Scholar
• Amin AA, Kokwaro GO. Antimalarial drug quality in Africa. J Clin Pharm Ther 2007;32:429-40
   PubMed Web of Science ®Google Scholar
• Caudron JM, Ford N, Henkens M, et al. Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Trop Med Int Health 2008;13:1062-72
   PubMed Web of Science ®Google Scholar
• Tabernero P, Fernandez FM, Green M, et al. Mind the gaps–the epidemiology of poor-quality anti-malarials in the malarious world–analysis of the WorldWide Antimalarial Resistance Network database. Malar J 2014;13:139
   PubMed Web of Science ®Google Scholar
• The participants of the WHO International Conference Combating Counterfeit Drugs. Building Effective International Collaboration. Declaration of Rome. Rome: 18 February 2006
   Google Scholar
• Newton PN, Lee SJ, Goodman C, et al. Guidelines for field surveys of the quality of medicines: a proposal. PLoS Med 2009;6:e52
   PubMed Web of Science ®Google Scholar
• Newton PN, Amin AA, Bird C, et al. The primacy of public health considerations in defining poor quality medicines. PLoS Med 2011;8:e1001139
   PubMed Web of Science ®Google Scholar
• Attaran A, Kendall M. Why and how to make an international crime of medicine counterfeiting. J Int Criminal Justice 2011;9:325-54
   Web of Science ®Google Scholar
• Clift C. Combating counterfeit, falsified and substandard medicines: defining the way forward?. Chatham House; London UK: 2010
   Google Scholar
• Nayyar GM, Breman JG, Newton PN, et al. Poor-quality antimalarial drugs in southeast Asia and sub-saharan Africa. Lancet Infect Dis 2012;12:488-96
   PubMed Web of Science ®Google Scholar
• Cockburn R, Newton PN, Agyarko EK, et al. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med 2005;2:e100
   PubMed Web of Science ®Google Scholar
• Newton PN, Tabernero P, Dwivedi P, et al. Falsified medicines in Africa: all talk, no action. Lancet Glob Health 2014;2:e509-10
   PubMed Web of Science ®Google Scholar
• Kaur H, Goodman C, Thompson E, et al. A nationwide survey of the quality of antimalarials in retail outlets in Tanzania. PLoS One 2008;3:e3403
   PubMed Web of Science ®Google Scholar
• Onwujekwe O, Kaur H, Dike N, et al. Quality of anti-malarial drugs provided by public and private healthcare providers in south-east Nigeria. Malar J 2009;8:22
   PubMed Web of Science ®Google Scholar
• WHO_Media_centre. Fact sheet N° 275, Spurious/falsely-labelled/falsified/counterfeit (SFFC) medicines. 2012
   Google Scholar
• Newton PN, Green MD, Fernandez FM. Impact of poor-quality medicines in the ‘developing’ world. Trends Pharmacol Sci 2010;31:99-101
   PubMed Web of Science ®Google Scholar
• Shretta R, Yadav P. Stabilizing supply of artemisinin and artemisinin-based combination therapy in an era of wide-spread scale-up. Malar J 2012;11:399
   PubMed Web of Science ®Google Scholar
• Newton PN, McGready R, Fernandez F, et al. Manslaughter by fake artesunate in Asia–will Africa be next? PLoS Med 2006;3:e197
   PubMed Web of Science ®Google Scholar
• Keoluangkhot V, Green MD, Nyadong L, et al. Impaired clinical response in a patient with uncomplicated falciparum malaria who received poor-quality and underdosed intramuscular artemether. Am J Trop Med Hyg 2008;78:552-5
   PubMed Web of Science ®Google Scholar
• Chaccour CJ, Kaur H, Mabey D, et al. Travel and fake artesunate: a risky business. Lancet 2012;380:1120
   PubMed Web of Science ®Google Scholar
• Newton PN, Fernandez FM, Plancon A, et al. A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Med 2008;5:e32
   PubMed Web of Science ®Google Scholar
• Blackstone EA, Fuhr JPJr, Pociask S. The health and economic effects of counterfeit drugs. Am Health Drug Benefits 2014;7:216-24
   PubMedGoogle Scholar
• Alfadl AA, Hassali MA, Ibrahim MI. Counterfeit drug demand: perceptions of policy makers and community pharmacists in Sudan. Res Social Adm Pharm 2013;9:302-10
   PubMed Web of Science ®Google Scholar
• Aldhous P. Counterfeit pharmaceuticals: murder by medicine. Nature 2005;434:132-6
   PubMed Web of Science ®Google Scholar
• Gaudiano MC, Di Maggio A, Cocchieri E, et al. Medicines informal market in Congo, Burundi and Angola: counterfeit and sub-standard antimalarials. Malar J 2007;6:22
   PubMed Web of Science ®Google Scholar
• Tougher S, Group AC, Ye Y, et al. Effect of the affordable medicines facility–malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data. Lancet 2012;380:1916-26
   PubMed Web of Science ®Google Scholar
• Martino R, Malet-Martino M, Gilard V, et al. Counterfeit drugs: analytical techniques for their identification. Anal Bioanal Chem 2010;398:77-92
   PubMed Web of Science ®Google Scholar
• Kaur HH, Fernandez FM, Green MD, et al. Antimalarial drug quality-methods to detect suspect drugs. Therapy 2010;7:49-57
   Google Scholar
• Ioset JR, Kaur H. Simple field assays to check quality of current artemisinin-based antimalarial combination formulations. PLoS One 2009;4:e7270
   PubMed Web of Science ®Google Scholar
• Leslie T, Kaur H, Mohammed N, et al. Epidemic of Plasmodium falciparum malaria involving substandard antimalarial drugs, Pakistan, 2003. Emerg Infect Dis 2009;15:1753-9
   PubMed Web of Science ®Google Scholar
• Website of the global parma health fund. Available from: www.gphf.org/web/en/minilab [Accessed 20 December 2014]
   Google Scholar
• Davies EC, Chandler CI, Innocent SH, et al. Designing adverse event forms for real-world reporting: participatory research in Uganda. PLoS One 2012;7:e32704
   PubMed Web of Science ®Google Scholar
• Bansal D, Malla S, Gudala K, et al. Anti-counterfeit technologies: a pharmaceutical industry perspective. Sci Pharm 2013;81:1-13
   PubMedGoogle Scholar
• Karunamoorthi K. The counterfeit anti-malarial is a crime against humanity: a systematic review of the scientific evidence. Malar J 2014;13:209
   PubMed Web of Science ®Google Scholar
• Jack A. Call for greater penalties for peddlers of fake antimalarials. In Financial Times 2014
   Google Scholar
• Mudur G. India to introduce death penalty for peddling fake drugs. BMJ 2003;327:414
   PubMedGoogle Scholar
• Ogunsola O. NAFDAC advocates death penalty for fake drug producers, peddlers. In Daily Independent; Nigeria: 2014
   Google Scholar
• Abdoulaye I, Chastanier H, Azondekon A, et al. Evaluation of public awareness campaigns on counterfeit medicines in Cotonou. Benin. Med Trop (Mars) 2006;66:615-18
   PubMedGoogle Scholar